IMR Press / RCM / Volume 24 / Issue 11 / DOI: 10.31083/j.rcm2411336
Open Access Review
Recent Advances in the Mechanisms of Cell Death and Dysfunction in Doxorubicin Cardiotoxicity
Show Less
1 National Clinical Research Center for Geriatric Diseases, the Second Medical Center, Chinese PLA General Hospital, 100853 Beijing, China
*Correspondence: (Dong Han); (Feng Cao)
Rev. Cardiovasc. Med. 2023, 24(11), 336;
Submitted: 12 April 2023 | Revised: 26 May 2023 | Accepted: 12 June 2023 | Published: 27 November 2023
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Despite recent advances in cancer therapy, anthracycline-based combination therapy remains the standardized first-line strategy and has been found to have effective antitumor actions. Anthracyclines are extremely cardiotoxic, which limits the use of these powerful chemotherapeutic agents. Although numerous studies have been conducted on the cardiotoxicity of anthracyclines, the precise mechanisms by which doxorubicin causes cardiomyocyte death and myocardial dysfunction remain incompletely understood. This review highlights recent updates in mechanisms and therapies involved in doxorubicin-induced cardiomyocyte death, including autophagy, ferroptosis, necroptosis, pyroptosis, and apoptosis, as well as mechanisms of cardiovascular dysfunction resulting in myocardial atrophy, defects in calcium handling, thrombosis, and cell senescence. We sought to uncover potential therapeutic approaches to manage anthracycline cardiotoxicity via manipulation of crucial targets involved in doxorubicin-induced cardiomyocyte death and dysfunction.

cell death
Graphical Abstract
View Full Image
82100372/National Natural Science Foundation of China
2022YFA1104700/National Key Research and Development Program of China
BX20200154/China Postdoctoral Science Foundation
2021MD703962/China Postdoctoral Science Foundation
Z211100002121048/Beijing Nova Program
7232159/Beijing Natural Science Foundation
Fig. 1.
Back to top